09:17 AM EST - Marvel Biosciences Corp : Announces it has successfully completed a large-scale engineering run of its novel solid amorphous dispersion formulation of MB-204 by Zhejiang Ausun Pharmaceutical Co., Ltd. The engineering run material will be utilized to support the ongoing toxicology studies of MB-204 being conducted by Pharmaron Inc. The engineering run is a key step forward to manufacturing the Company's lead product at a large scale for FDA Phase I human trials. Marvel Biosciences Corp
shares V.MRVL are trading up one cent at $0.12.
